HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Yahoo Finance

Summary This reports provides a data-driven overview of the current and future competitive landscape in HER2- Breast Cancer therapeutics. Synopsis
New York, Oct. 05, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” – https://www.reportlinker.com/p06326010/?utm_source=GNW
– In 2022, there will be more than one million incidence cases of HER2- BC across 16 pharmaceutical markets.
– There are several marketed innovator drugs for the treatment of HER2- BC, mostly kinase inhibitors.
– A total of seven pipeline drugs for HER2- BC are in pre-registration phase and 42 drugs are in Phase III.
– Commercial sponsors dominate clinical trial development in HER2- BC, with the US emerging as the key country for conducting Phase III trials in HER2- BC.
– Partnership was the most common type of deal in North America and Europe, while licensing agreements were the most prominent deal type in South America and Africa.
– Within the next 24 months, several new product launches within HER2- Breast Cancer space are expected.

HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include –
– Disease Landscape
– Disease Overview
– Epidemiology Overview
– Treatment Overview
– Marketed Products Assessment
– Breakdown by Mechanism of Action, Molecule Type, Route of Administration
– Product Profiles with Sales Forecast
– Pricing and Reimbursement Assessment
– Retail or Manufacturer Price of Products
– Time to Pricing and Time to Reimbursement
– Pipeline Assessment
– Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
– Product Profiles with Sales Forecast
– Late-to-mid-stage Pipeline Drugs
– Phase Transition Success Rate and Likelihood of Approval
– Clinical Trials Assessment
– Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
– Enrolment Analytics, Site Analytics, Feasibility Analysis
– Deals Landscape
– Mergers, Acquisitions, and Strategic Alliances by Region
– Overview of Recent Deals
– Commercial Assessment
– Key Market Players
– Future Market Catalysts

Reasons to Buy
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the HER2- Breast Cancer market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2- Breast Cancer market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06326010/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


Fewer still earn multiple regulatory approvals. Bluebird Bio is one of the lucky exceptions after earning FDA approval for Zynteglo and Skysona in the third quarter. An exodus of executives, a precariously low cash position, and a fierce competitive landscape suggest the gene therapy pioneer still may not live up to expectations.
Lockhart, south of Austin, had been a finalist for this massive semiconductor factory. Micron said Oct. 4 it will invest up to $100 billion to build the fabrication facility in Central New York, with the help of $5.5 billion in incentives.
What happened Shares of Sorrento Therapeutics (NASDAQ: SRNE), a biotech company that specializes in oncology and pain therapies, dropped 23.4% in September, according to data from S&P Global Intelligence.
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
OPEC+ will cut oil production by 2 million barrels per day amid looming demand concerns and the ongoing friction between the West and Russia over the war in Ukraine.
Costco offers a very simple proposition to its members. Basically, Costco offers no frills — its stores aren't just called warehouses, they actually are warehouses — and items are basically just stacked on pallets. Costco also puts relentless pressure on its vendors to squeeze out every penny of cost from each item.
Microsoft researchers recently warned of 'productivity paranoia' among managers about their hybrid workforce.
It's been a tough time for the airline industry lately. It recently made a change where its Rapid Rewards Members can now achieve A-List or A-List Preferred tier status much quicker, which will make it easier to accumulate points that can be used for such perks as priority boarding and the ability to make a same day change with no difference in base fare. The company also introduced a feature that lets customers change their boarding group for an added fee starting at $30, either online or via the Southwest app, within 24 hours of departure.
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
SIGA Technologies (NASDAQ: SIGA), a pharmaceutical company that specializes in health security countermeasures against biological, chemical, radiological, and nuclear attacks, along with vaccines and therapies to treat emerging infectious diseases, saw its shares fall 31.7% in September, according to data from S&P Global Intelligence. The company manufactures TPOXX (tecovirimat), a vaccine against monkeypox. On Sept. 19, the Food and Drug Administration (FDA) said that the vaccine, initially developed to prevent smallpox, should be restricted to only those patients with severe monkeypox disease or at high risk of severe cases of monkeypox, including people with weakened immune systems or skin conditions, such as eczema or HIV that is not virally suppressed.
New research based on the life-cycle model says that people should strive for a consistent standard of living through their lives.
(Bloomberg) — The OPEC+ alliance agreed to its biggest production cut since the start of the pandemic in Vienna on Wednesday, a move that drew a swift rebuke from the US and prompted Goldman Sachs Group Inc. to increase its price forecast for global benchmark Brent crude this quarter.Most Read from BloombergMusk Revives $44 Billion Twitter Bid, Aiming to Avoid TrialTrump Says US Agency Packed Top-Secret Documents. These Emails Suggest Otherwise.One Big Option Trade Fueled S&P 500’s Midday Jump,
Creating income for retirement is one of the biggest challenges American workers have in planning for how they will be able to live comfortably once they stop working. One of the most common ways to create this income is to … Continue reading → The post If You Have This Much Money Saved You Don't Need an Annuity appeared first on SmartAsset Blog.
Exxon Mobil (XOM) stock surged Wednesday after it signaled natural gas prices would support already strong third-quarter expectations. Despite steep growth estimates, the energy giant projects it will not match its record profits from Q2 as oil prices have retreated along with refining and chemical segment profits. Exxon reported its operating profit could come in at around $11 billion in…
The OPEC+ group of oil-producing countries has agreed on a drastic cut to the global supply. The speculation has helped oil reverse its recent declines. William Watts explained why the actual production cuts by the OPEC+ group might not turn out as expected.
President Biden has had to deal with a lot in the first two years of his presidency. Between the pandemic, inflation, and a war in Eastern Europe that has no signs of abating anytime soon, the President has had a lot on his plate. Arguably the biggest part of the meal he needs to get his hands on is gas prices, however, and this week he found out that the oil cartel OPEC+ won't be lending him a helping hand anytime soon.
About 60% of managers say it’s likely that remote workers will be cut first if their company needs to do layoffs.
Our Next Energy, which involves several former leaders of Apple’s secretive car project, has plans for its factory to produce enough cells annually for 200,000 EVs by the end of 2027.
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
(Reuters) -The largest U.S. oil trade groups said on Tuesday that they have "significant concerns" that the Biden administration is considering limiting fuel exports to lower consumer prices and urged top officials to take the option off the table, according to a letter seen by Reuters. The joint letter from the American Petroleum Institute and the American Fuel and Petrochemical Manufactures to Energy Secretary Jennifer Granholm represents the latest volley in a clash between the oil industry and the Biden administration over high energy prices. President Joe Biden has made battling an energy-led surge in consumer prices a top priority and has repeatedly chided oil companies for earning bumper profits at a time of record gasoline prices.


Add a Comment

Your email address will not be published. Required fields are marked *